NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $679,000 | +4.6% | 37,800 | 0.0% | 0.02% | +9.1% |
| Q2 2021 | $649,000 | +3.3% | 37,800 | +20.4% | 0.02% | -12.0% |
| Q1 2021 | $628,000 | +17.6% | 31,400 | 0.0% | 0.02% | +8.7% |
| Q4 2020 | $534,000 | -12.0% | 31,400 | -14.2% | 0.02% | -20.7% |
| Q3 2020 | $607,000 | -37.4% | 36,600 | -12.6% | 0.03% | -37.0% |
| Q2 2020 | $970,000 | +29.7% | 41,900 | 0.0% | 0.05% | +2.2% |
| Q1 2020 | $748,000 | +14.7% | 41,900 | +38.7% | 0.04% | +66.7% |
| Q4 2019 | $652,000 | +167.2% | 30,200 | +125.4% | 0.03% | +145.5% |
| Q3 2019 | $244,000 | -52.1% | 13,400 | -6.3% | 0.01% | -50.0% |
| Q2 2019 | $509,000 | +5.2% | 14,300 | -0.7% | 0.02% | +4.8% |
| Q1 2019 | $484,000 | +2.3% | 14,400 | 0.0% | 0.02% | -8.7% |
| Q4 2018 | $473,000 | -46.1% | 14,400 | 0.0% | 0.02% | -30.3% |
| Q3 2018 | $878,000 | +21.4% | 14,400 | -2.7% | 0.03% | +17.9% |
| Q2 2018 | $723,000 | -55.8% | 14,800 | -3.9% | 0.03% | -54.8% |
| Q1 2018 | $1,636,000 | – | 15,400 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 432,952 | $1,385,000 | 0.91% |
| GREAT POINT PARTNERS LLC | 447,820 | $1,433,000 | 0.34% |
| Birchview Capital, LP | 128,000 | $410,000 | 0.29% |
| Edgestream Partners, L.P. | 1,047,636 | $3,352,000 | 0.26% |
| Rhenman & Partners Asset Management AB | 550,000 | $2,068,000 | 0.22% |
| CM Management, LLC | 50,000 | $160,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 430,037 | $1,376,000 | 0.17% |
| PDT Partners, LLC | 307,953 | $985,000 | 0.15% |
| Virtus ETF Advisers LLC | 72,018 | $230,000 | 0.09% |
| ALGERT GLOBAL LLC | 476,412 | $1,525,000 | 0.09% |